Albireo Pharma Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma or view top-rated stocks.

Wall Street analysts have given Albireo Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Albireo Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Albireo Pharma.

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.90) by $0.60. The biopharmaceutical company had revenue of $2.72 million for the quarter, compared to the consensus estimate of $2.23 million. Albireo Pharma had a negative trailing twelve-month return on equity of 71.22% and a negative net margin of 751.53%.
View Albireo Pharma's earnings history.

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALBO shares have increased by 82.2% and is now trading at $32.12.
View which stocks have been most impacted by COVID-19.

8 brokerages have issued 1 year price objectives for Albireo Pharma's stock. Their forecasts range from $65.00 to $82.00. On average, they expect Albireo Pharma's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 124.2% from the stock's current price.
View analysts' price targets for Albireo Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Albireo Pharma include Rocket Pharmaceuticals (RCKT), Amicus Therapeutics (FOLD), Cryoport (CYRX), Xencor (XNCR), Amarin (AMRN), Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), Morphic (MORF), CytoDyn (CYDY) and Kura Oncology (KURA).
View all of ALBO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALBO stock can currently be purchased for approximately $32.12.

Albireo Pharma has a market capitalization of $613.94 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis.

Albireo Pharma employs 90 workers across the globe.

The official website for Albireo Pharma is www.albireopharma.com.

Albireo Pharma is headquartered at 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555 or via email at [email protected]